Telix Pharmaceuticals Stock

Telix Pharmaceuticals Net Margin

Delisted·Jun 19, 2026

The Net Profit Margin of Telix Pharmaceuticals (TLX.AX) as of Aug 21, 2026 is -0.89 %. In the previous year, Net Profit Margin was 6.52 % — a change of -113.59% (lower).

Net Margin

-0.89 %

YoY

-113.59%

Last updated:

Net Profit Margin of Telix Pharmaceuticals is 2026 -0.89 % . Net Profit Margin of Telix Pharmaceuticals was 2025 6.52 % . It decreases by -113.59% lower compared to the previous year.

Telix Pharmaceuticals's net margin stands at -0.9%, up from -1,059.9% several years earlier.

Access this data via the Eulerpool API
Get Free API Key

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Net Profit Margin of Telix Pharmaceuticals is -0.89 % in 2026.

Net Profit Margin of Telix Pharmaceuticals changed from 6.52 % to -0.89 %, representing a -113.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API
Get Free API Key

Margins — Telix Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Telix Pharmaceuticals